A Randomized Open-label Phase II Study of Letrozole Plus Afatinib Versus Letrozole Alone in First-line Treatment of Advanced ER+, HER2- Postmenopausal Breast Cancer With Low ER Expression
Phase of Trial: Phase II
Latest Information Update: 27 Dec 2019
Price : $35 *
At a glance
- Drugs Afatinib (Primary) ; Letrozole
- Indications Adenocarcinoma; Advanced breast cancer
- Focus Therapeutic Use
- 11 Dec 2019 Status changed from completed to discontinued.
- 30 Dec 2018 The study has been completed in Spain, according to European Clinical Trials Database.
- 03 Dec 2018 Status changed from active, no longer recruiting to completed.